In Q4 FY2026 Zydus Lifesciences reported consolidated revenue from operations of ₹7,587.0 Cr, up from ₹6,527.9 Cr in Q4 FY2025, with volume/portfolio growth across Pharmaceuticals and Consumer Products. Consolidated net profit rose to ₹1,272.5 Cr in Q4 FY2026 from ₹1,170.9 Cr in Q4 FY2025, while profit before tax after exceptional items was broadly flat at ₹1,659.7 Cr (Q4 FY2025: ₹1,672.0 Cr). Results were affected by a net foreign-currency gain of ₹644.9 Cr and exceptional items of ₹397.5 Cr (one-time settlement) partly offset by higher finance costs of ₹123.0 Cr in the quarter. Management...
Total revenue from operations (Consolidated) Q4 FY2026
₹7,587.0 Cr
vs ₹6,527.9 Cr in Q4 FY2025
Net profit (Consolidated) Q4 FY2026
₹1,272.5 Cr
vs ₹1,170.9 Cr in Q4 FY2025
Profit before exceptional items, tax and share of JVs (Consolidated) Q4 FY2026
₹2,057.2 Cr
vs ₹1,891.6 Cr in Q4 FY2025
Profit before tax and share of JVs (after exceptional items) Q4 FY2026
